**
In an alarming revelation, internal documents have surfaced indicating that top officials from the Environmental Protection Agency (EPA) met with Bayer CEO Bill Anderson last year to discuss legal strategies concerning the company’s glyphosate herbicides, including the contentious Roundup. This meeting, held on 17 June, occurred just months prior to a series of actions taken by the Trump administration that appeared to bolster Bayer’s position in ongoing litigation involving claims that its products cause cancer.
High-Level Meeting Under Scrutiny
The records obtained through a Freedom of Information Act request reveal that the meeting was not merely a casual exchange but a significant gathering involving key EPA figures, including Lee Zeldin, the agency’s administrator, and Nancy Beck, the principal deputy assistant administrator for the Office of Chemical Safety and Pollution Prevention. The agenda explicitly noted that Bayer intended to discuss legal challenges and potential Supreme Court actions related to glyphosate.
Bayer has been embroiled in numerous lawsuits filed by individuals alleging that their use of glyphosate products has led to cancer diagnoses. Critics argue that these lawsuits spotlight Bayer’s failure to adequately warn consumers of the associated risks, a claim supported by extensive research over several years. With the company facing billions in settlements, Bayer’s strategy hinges on persuading the Supreme Court to accept its argument that the absence of an EPA mandate for cancer warnings absolves it of liability.
In a statement, Bayer characterized the meeting as standard procedure within the regulatory framework, asserting that it has maintained transparency regarding its position on glyphosate litigation.
Political Influence and Corporate Power
Environmental advocates have reacted with alarm to the implications of this meeting. Nathan Donley, director of environmental health science at the Centre for Biological Diversity, highlighted the troubling reality of corporate influence in regulatory processes. “When the CEO of one of the world’s largest companies can engage directly with political appointees at the EPA, it underscores the disproportionate power these corporations wield,” he remarked.
The meeting not only reflects a concerning trend of corporate lobbying but also raises questions about whether the voices of those harmed by glyphosate exposure are being adequately represented in regulatory discussions. Experts have expressed unease about the apparent prioritisation of corporate interests over public health.
Administration Actions Following the Meeting
Since the June meeting, the Trump administration has taken several actions that suggest a concerted effort to support Bayer’s legal battles. In December 2025, the administration’s solicitor general filed a brief advocating for the Supreme Court to hear Bayer’s case, which the court subsequently agreed to, setting a hearing date for 27 April. Furthermore, in February 2026, the White House invoked the Defense Production Act to protect glyphosate production, effectively providing legal immunity to manufacturers like Bayer.
Critics argue that these moves are indicative of an administration more concerned with corporate profits than public safety. Whitney Di Bona, a consumer safety advocate, expressed her concerns, stating, “It’s troubling that the CEO of a major pesticide company can privately meet with EPA officials to discuss ways to limit their liability.” This raises an essential question: Are the voices of those who have suffered due to glyphosate being ignored in favour of corporate interests?
A Call for Greater Accountability
The meeting and the ensuing actions by the Trump administration have ignited discussions about the ethical implications of regulatory practices. Naomi Oreskes, a Harvard professor, pointed out the disparity in access to government officials between industry leaders and the average citizen. “It mirrors a pattern where corporate executives have a level of access to decision-makers that ordinary people simply do not,” she stated.
Zen Honeycutt, founder of Moms Across America, echoed this sentiment, asserting that the influence of chemical companies over regulatory agencies is a long-standing issue. Her organisation has repeatedly sought engagement with the EPA to address concerns about pesticide safety but has seen little actionable response.
Why it Matters
The revelations surrounding the EPA’s meeting with Bayer executives underscore a growing concern about the integrity of regulatory bodies and their susceptibility to corporate influence. As the debate over glyphosate continues, the stakes are high—not just for Bayer, but for public health and safety. With thousands of individuals alleging harm from these products, it is crucial that regulatory processes remain transparent and prioritise the welfare of the public over corporate interests. This situation serves as a stark reminder of the need for vigilance and advocacy in the face of powerful corporate lobbying, ensuring that the voices of those affected are heard and valued in the ongoing discourse around pesticide regulation.
